Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Zevra Therapeutics, Inc.’s reported figures.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s EBITDA?
- Zevra Therapeutics, Inc. (ZVRA) reported EBITDA of $17.14M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s EBITDA changed year-over-year?
- Zevra Therapeutics, Inc.'s EBITDA increased by 124.7% year-over-year, from -$69.39M to $17.14M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s EBITDA has grown at a 60.1% compound annual growth rate (CAGR), from $8.16M to -$53.59M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Zevra Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude